


Remarks

The basis for claim 59 is original claim 1 and specification page 3, lines 2 – 3; for claim 62 is page 24, line 17 and page 21, line 24; for claim 63 is original claim 43; for claim 64 is original claim 7; for claim 65 is specification pages 42 – 45; for claim 66 is specification page 36 (formulations A and B) and Table 1, page 41; for claim 67 is Table 1; for claim 77 is Formulations A – K and Table 1; for claim 78 is formulations A – K and Table 1 (calculated by dividing the drug weight by the total weight of composition in claim 77 embodiments); for claim 79 is the same as claims 77 and 78); for claim 87 see claim 1; for claim 89, original claim 50; for claim 97, Table 1; and for claim 98, specification page 45, lines 19 – 24. The remaining new claims have direct antecedents in the original claim set. None of the amendments introduce new matter.

This application is now believed to be in condition for examination on the merits.

Respectfully submitted,



Max Hensley, Reg. No. 27,043
Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA 94404.
Telephone: (650) 522-5535
Facsimile: (650) 522-5575

Date: March 17, 2006